Decreased plasma efavirenz concentrations in a patient receiving rifabutin

American Journal of Health-System Pharmacy

Volumn 67, Issue 19, 2010, Pages 1611-1614

  Hsu, Oliver ^a   Hill, Catherine J ^b   Kim, Mina ^a   Tan, Benny ^c   O'Brien, John G ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Santa Clara Valley Health & Hospital System   (United States)

^c CVS Caremark   (United States)

^d Valley Health   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiinfective agents; Antiretroviral agents; Azithromycin; Blood levels; Clarithromycin; Dexamethasone; Dosage; Drug interactions; Efavirenz; Emtricitabine; Enoxaparin; Ethambutol; Ganciclovir; Isoniazid; Metabolism; Metformin; Mycobacterium avium intracellulare infection; Pyrazinamide; Pyridoxine; Rifabutin; Rifampin; Sulfamethoxazole; Tenofovir; Trimethoprim

Indexed keywords

ATAZANAVIR; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DEXAMETHASONE; EFAVIRENZ; EMTRICITABINE; ENOXAPARIN; ETHAMBUTOL; FLUCONAZOLE; FOSCARNET SODIUM; GANCICLOVIR; ISONIAZID; METFORMIN; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SULFAMETHOXAZOLE; TENOFOVIR; TRIMETHOPRIM; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ASEPTIC MENINGITIS; ATYPICAL MYCOBACTERIOSIS; CASE REPORT; CD4+ T LYMPHOCYTE; DIPLOPIA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEADACHE; HEARING LOSS; HIV TEST; HUMAN; LIMB WEAKNESS; LUMBAR PUNCTURE; MALAISE; MALE; PARESTHESIA; PRIORITY JOURNAL; RADICULOPATHY; THRUSH; URINE RETENTION; VIRUS LOAD; DRUG EFFECT; DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; ISOLATION AND PURIFICATION; METHODOLOGY; MYCOBACTERIUM INTRACELLULARE AVIUM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG INTERACTIONS; HUMANS; MALE; MENINGITIS, ASEPTIC; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RIFABUTIN; VIRAL LOAD;

EID: 79952112843     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090516     Document Type: Article

References (17)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services; 2009:1-161.
2. Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb; 2009 Sep.
3. Spradling P, Drociuk D, McLaughlin S et al. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infec Dis. 2002; 35:1106-12. (Pubitemid 35239471)
4. Stahle L, Moberg L, Svensson JO et al. Efavirenz plasma concentrations in HIV-infected patients: inter- and intra individual variability and clinical effects. Ther Drug Monit. 2004; 26:267-70. (Pubitemid 38703012)
5. Kuper JI, D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000; 39:203-14.
6. Horn JR, Hansten PD, Chan L. New tool to evaluate drug interactions. Ann Pharmacother. 2007; 41:674-80.
7. Gutierrez F, Nvarro A, Padilla S et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41:1648-53. (Pubitemid 41691605)
8. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patient. AIDS. 2001; 15:71-5. (Pubitemid 32055781)
9. Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A et al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr. 2005; 39:551-6. (Pubitemid 41098469)
10. La Porte CJ, Back DJ, Blashke T et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006; 3:4-14.
11. Balfour HH, Fletcher CV, Erice A et al. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother. 1996; 40:2721-6. (Pubitemid 26404332)
12. Kaiser L, Perrin L, Hirschel B et al. Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis. 1995; 172:225-7.
13. Lewthwaite P, Gibbons S, Vilar FJ et al. Efavirenz, rifampicin and rifabutin - a case for therapeutic drug monitoring? Antivir Ther. 2003; 8(suppl 1): abstract 851.
14. Weiner M, Benator D, Peloquin CA et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis. 2005; 41:1343-9. (Pubitemid 41532682)
15. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and rifampicin-containing antituberculosis regimen. J Antimicrob Chemother. 2006; 58:1017-23.
16. Lindfelt T, O'Brien J, Mcclain M et al. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2008 Oct 25.
17. Intelence (etravirine) package insert. Raritan, NJ: Tibotec Therapeutics; 2009 Aug.